Pharmafile Logo

#RemoteDetailing

- PMLiVE

Dollo’s law

Why you and your company may be worse, rather than better, than you used to be

- PMLiVE

Nobel Prize in Medicine awarded to pair of scientists behind mRNA COVID-19 vaccines

Katalin Karikó and Drew Weissman’s findings paved the way for effective mRNA vaccines

A female clinical using her smartphone wearing blue scrubs

Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital

Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...

Graphite Digital

- PMLiVE

HOW TO TRANSFORM YOUR HEALTHCARE BRAND MARKETING FROM MULTI-CHANNEL TO OMNICHANNEL

In a previous blog, we outlined the role of omnichannel in healthcare and the importance of personalised communications with the suggestion of using modular content to support an omnichannel approach.  No...

IGNIFI

Biogen Idec building

Biogen’s Actemra biosimilar approved by FDA to treat adult and paediatric arthritis

Tofidence is now the first biosimilar referencing Actemra to gain approval from the US regulator

regeneron headquarters

Regeneron’s odronextamab granted FDA priority review for non-Hodgkin lymphoma

The regulator is expected to make a decision on the drug by the end of March 2024

- PMLiVE

The impact of prostate cancer on global health

Noel Clarke talks to PME about current research for prostate cancer and how treatments have improved over the last decade

- PMLiVE

Improvement in rare disease diagnosis and care

By Megan Allen, Kristina Rodriguez and Michelle Kim

- PMLiVE

Contagious Conversations: Exploring Infectious Disease in the Digital Age

As the world of medicine continues to evolve, it's crucial to stay ahead of the curve. In this dynamic era, digital communications have emerged as a driving force in discussions...

Medscape Education

- PMLiVE

Austrian State Secretary to speak at FlyPharma Europe 2023

Register now to get industry insights from a host of expert industry speakers

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links